22Nd Century Group, Inc.
XXII22Nd Century Group, Inc. in brief
22Nd Century Group, Inc. is a listed company in the Pharmaceutical industry, based in Williamsville, Indiana, USA. It was founded in 1998. Its market value was $0 M on 29 October 2026, which makes it the 28,310th largest listed company in the world and the 4,527th largest in the USA on this site. In the year to December 2025 it had sales of $18 M and a net loss of $5 M. It employs about 67 people and Lawrence Firestone is its chief executive. Its largest product and service lines by sales in 2025 were Contract Manufacturing (99%), Cigarettes (73%) and Filtered Cigars (23%). Its shares trade under the symbol XXII (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About 22Nd Century Group, Inc.
22nd Century Group is a Plant Biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene editing and modern plant breeding. The headquarters is in USA.
22nd Century Group company annual revenue was 62 million USD and annual net loss was -59 million USD as on Dec-2022.
22Nd Century Group, Inc. timeline
- 1998
- 🏁· approximateFounded
- 2005
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- ✎Renamed 22nd Century Group, Inc.Formerly Touchstone Mining LTD.
- 2022
- 💰Record revenue of $40 millionFY2022, the highest of the 8 years on record.
Events of 22Nd Century Group, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,417 (Jan 2020) · #2,934 (Jan 2021) · #3,030 (Jan 2022) · #3,729 (Dec 2022) · #4,654 (Jul 2023) · #4,557 (Jan 2024) · #2,486 (Mar 2026) · #4,172 (Aug 2026) · #4,458 (Oct 2026) · #4,530 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.0×
- Price / book
- 0.0×
- Free cash flow yield
- -2431.2%
- Net margin (TTM)
- -27.0%
- Operating margin
- -65.8%
- Return on equity
- -24.9%
- Liabilities / assets
- 31.6%
- Net debt
- $-6M
- Revenue growth
- -27.9%
- R&D / revenue
- 3.9%
- Revenue per employee
- $263 K
- Profit per employee
- $-75 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $18M | -27.9% | $-12M | $-5M | -28.7% |
| Dec 2024 | $24M | -24.3% | $-14M | $-15M | -62.2% |
| Dec 2023 | $32M | -20.5% | $-45M | $-141M | -437.2% |
| Dec 2022 | $41M | +30.9% | $-34M | $-60M | -147.7% |
| Dec 2021 | $31M | +10.1% | $-28M | $-33M | -105.4% |
| Dec 2020 | $28M | +8.8% | $-19M | $-20M | -70.1% |
| Dec 2019 | $26M | -2.3% | $-24M | $-27M | -102.8% |
| Dec 2018 | $26M | — | $-24M | $-8M | -30.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-8M | $0M | $-8M | $-52.87 | — |
| Dec 2024 | $-14M | $0M | $-14M | $-45711.05 | — |
| Dec 2023 | $-55M | $5M | $-60M | $-15925.99 | — |
| Dec 2022 | $-52M | $4M | $-55M | $-4.65 | — |
| Dec 2021 | $-23M | $1M | $-24M | $-0.21 | — |
| Dec 2020 | $-16M | $0M | $-16M | $-0.14 | — |
| Dec 2019 | $-15M | $1M | $-15M | $-0.21 | — |
| Dec 2018 | $-18M | — | — | $-0.06 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $3M (-29.9% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 3, 20268-KCurrent reportBylaws amended
- Oct 28, 20268-KCurrent reportMaterial agreement
- Oct 23, 20268-KCurrent reportOther events
- Oct 22, 20268-KCurrent reportResults of operations · Other events
- Sep 1, 20268-KCurrent reportRegulation FD disclosure
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 5, 20268-KCurrent reportShareholder vote
- Jul 2, 20268-KCurrent reportAgreement ended
- Jun 23, 2026DEF 14AProxy statement
- Jun 11, 20268-KCurrent reportShareholder vote
- Jun 9, 20268-K/ACurrent report (amended)Material agreement · Unregistered share sale · Bylaws amended
Official filings of 22Nd Century Group, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $18 M
- Operating income
- $-12 M
- Net income
- $-5 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $27 M
- Total liabilities
- $9 M
- Total equity
- $16 M
As of December-2025
Top 19 institutional investors in 22Nd Century Group, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Anson Funds Management LP | 80,000 | +45,435 (+131.45%) | 11.20% | $0 M | Nov 13, 2026 |
| 2 | UBS Group AG | 5,715 | +2,507 (+78.15%) | 0.80% | $0 M | Nov 10, 2026 |
| 3 | Tower Research Capital LLC (TRC) | 1,199 | New | 0.17% | $0 M | Nov 16, 2026 |
| 4 | Robinhood Markets, Inc. | 69 | — | 0.01% | $0 M | Nov 18, 2026 |
| 5 | Caitong International Asset Management Co., Ltd | 8 | +7 (+700.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 6 | Morgan Stanley | 7 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 7 | Osaic Holdings, Inc. | 7 | -1 (-12.50%) | 0.00% | $0 M | Nov 12, 2026 |
| 8 | Fifth Third Bancorp | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 9 | Steward Partners Investment Advisory, LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 10 | BlackRock, Inc. | 2 | +1 (+100.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 11 | Jpmorgan Chase & Co | 1 | New | 0.00% | $0 M | Nov 12, 2026 |
| 12 | Barclays PLC | 1 | -163 (-99.39%) | 0.00% | $0 M | Nov 6, 2026 |
| 13 | Northwestern Mutual Wealth Management Co | 1 | New | 0.00% | $0 M | Nov 13, 2026 |
| 14 | Allworth Financial LP | 1 | New | 0.00% | $0 M | Nov 17, 2026 |
| 15 | NewEdge Advisors, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 16 | IFP Advisors, Inc | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 17 | Gables Capital Management Inc. | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 18 | Kiker Wealth Management, LLC | 1 | New | 0.00% | $0 M | Nov 16, 2026 |
| 19 | William Mack & Associates, Inc. | 1 | New | 0.00% | $0 M | Oct 27, 2026 |
Insider trading at 22Nd Century Group, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Andrew ArnoDirector | Grant or award | +17,295 | — | — | 17,481 | Form 4 |
| filed | David N. KeysDirector | Grant or award | +12,578 | — | — | 14,696 | Form 4 |
| filed | Jonathan StaffeldtVP and Deputy General Counsel | Grant or award | +37,146 | — | — | 37,871 | Form 4 |
| filed | Lawrence FirestoneChief Executive Officer, Director | Grant or award | +66,824 | — | — | 68,129 | Form 4 |
| filed | Arvil S. MarionVP of Mfg. Operations* | Grant or award | +32,429 | — | — | 33,062 | Form 4 |
| filed | Robert P. ManfredoniaEVP of Sales and Marketing | Grant or award | +32,429 | — | — | 33,062 | Form 4 |
| filed | Daniel A. OttoChief Financial Officer | Grant or award | +37,146 | — | — | 37,871 | Form 4 |
| filed | Lucille S. SalhanyDirector | Grant or award | +11,006 | — | — | 11,114 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: 22Nd Century Group, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-57.8 reverse split ; 1-for-20 reverse split ; 1-for-14.99 reverse split ; 1-for-22.99 reverse split ; 1-for-135.14 reverse split ; 1-for-16 reverse split ; 1-for-14.99 reverse split
Trading halts
- 2026-11-05 00:50 UTC, code T3, resumed 14:00 UTC
- 2026-09-01 16:31 UTC, code LUDP, resumed 16:36 UTC
- 2026-09-01 16:24 UTC, code LUDP, resumed 16:29 UTC
- 2026-06-11 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-01-24 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 303,014 shares at $0.10
- : 910,704 shares at $0.10
- : 377,932 shares at $0.09
- : 4.0 M shares at $0.20
- : 3.9 M shares at $0.22
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
22Nd Century Group, Inc. scorecard#
Passes 7 of the 20 checks that could be worked out: strongest in financial health (3 of 5), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.0×Price to book 0.0× against Pharmaceutical's median of 3.2×.
- ✓Price to sales below its peers' median0.0×Price to sales 0.0× against Pharmaceutical's median of 3.5×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-27.9%Revenue down 27.9% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-24.3%-24.3% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-24.3%-24.3% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-52.87 vs -45711.05Diluted EPS -52.87 in fiscal 2025 against -45711.05 the year before (report's currency).
- ✓Net income higher than five years earlier-$5 M-$5 M in fiscal 2025 against -$20 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-65.8%-65.8% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-51.1%-51.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-65.8%-65.8% in fiscal 2025 against -83.1% in 2022.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.43 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.05 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $6 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-20.95Z-score -20.95 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from 22Nd Century Group, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -65.8% | 1.8% | |
| Net margin | -28.7% | -1.5% | |
| Return on equity | -51.1% | -0.9% | |
| Revenue growth, 3 years a year | -24.3% | 2.5% | |
| Revenue growth | -27.9% | 7.3% | |
| Debt to equity | 0.05× | 0.66× |
4of 9on the Piotroski tests of financial strength
- Revenue fell 27.9% against the year before.
- Net loss of $5 million, the 16th loss-making year in a row.
- Free cash flow was negative: -$8 million.
- Receivables grew 111% while revenue grew -28%: customers are paying later, or sales were booked ahead of cash.
22Nd Century Group, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 18−27.9%100% | 24−24.3%100% | 32−20.5%100% | 41r62+30.9%100% | 31+10.1%100% | 28+8.8%100% | 26−2.2%100% | 26+59.2%100% | 17+35.2%100% | 12—100% | |
| Cost of revenue | 10−28.7%57.9% | 14—58.6% | — | — | — | — | 26+1.1%99.9% | 26+47.5%96.6% | 17+36.2%104% | 13—103% | |
| Gross profit | — | — | — | — | — | — | 0.0−98.4%0.1% | 0.9—3.4% | −0.7—−4.3% | −0.4—−3.5% | |
| Research and development | 0.7−39.3%3.9% | 1.1−57.1%4.6% | 2.6−26.1%8.2% | 3.6r6.6−8.5%8.8% | 3.9—12.6% | — | 8.1−46.2%31.2% | 15+345%56.7% | 3.4+43.8%20.3% | 2.3—19.1% | |
| Selling, general and administrative | 7.6−26.2%43.2% | 10−66.9%42.2% | 31−3.6%96.5% | 32r45+24.4%79.6% | 26r26+73.1%83.7% | 15+15.6%53.3% | 13r13+50.9%50.1% | 8.6r8.6+3.7%32.5% | 8.3—49.9% | — | |
| Selling and marketing | — | — | — | — | — | — | — | 0.9−20.2%3.5% | 1.2−26.5%7.0% | 1.6—12.9% | |
| General and administrative | — | — | — | — | — | — | — | 7.7+7.6%29.0% | 7.1+14.9%42.9% | 6.2—50.4% | |
| Operating expenses | 8.4−27.0%47.9% | 12−68.1%47.4% | 36+2.1%113% | 35r58+18.7%87.6% | 30r30+45.0%96.6% | 21−12.6%73.4% | 24r24−5.4%91.3% | 25r25+97.9%94.3% | 13+14.9%75.9% | 11—89.2% | |
| Operating income | −12—−65.8% | −14—−57.2% | −45—−140% | −34r−57—−83.0% | −28—−91.8% | −19—−68.2% | −24r−24—−91.2% | −24r−24—−90.9% | −13—−80.1% | −11—−92.7% | |
| Interest expense and finance costs | 1.5−30.5%8.3% | 2.1−77.6%8.6% | 9.4+16929%29.1% | 0.1r0.4−5.2%0.1% | 0.1−19.4%0.2% | 0.1+28.6%0.3% | 0.1r0.1+409%0.2% | 0.0r0.0−62.2%0.0% | 0.0−22.9%0.2% | 0.0—0.3% | |
| Share of profit of associates | — | — | — | — | — | — | — | — | 0.0−86.9%0.0% | 0.1—0.5% | |
| Other non-operating income (expense) | −1.6—−9.0% | −1.5—−6.2% | −9.7—−30.1% | −2.9r−3.1—−7.2% | −4.2—−13.5% | −0.5—−1.7% | −3.0r−3.0−119%−11.6% | 16r16+5829%60.7% | 0.3—1.6% | −0.2—−1.6% | |
| Income before tax | −13—−74.7% | −15—−63.4% | −55—−170% | −37r−60—−90.2% | −33—−105% | −20—−70.0% | −27r−27—−103% | −8.0r−8.0—−30.1% | −13—−78.5% | −12—−94.3% | |
| Income tax | −0.0−193%−0.2% | 0.0−36.2%0.1% | 0.0+124%0.1% | 0.0r−0.4+50.0%0.1% | 0.0−63.2%0.0% | 0.0—0.1% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | −13—−74.6% | −15—−63.6% | −55—−170% | −37—−90.3% | — | — | — | — | — | — | |
| Income from discontinued operations | 8.1+2336%45.8% | 0.3—1.4% | −86—−267% | −23—−57.4% | — | — | — | — | — | — | |
| Net income including minority interests | −5.1—−28.7% | −15—−62.2% | −141—−437% | −60—−148% | −33—−105% | −20—−70.1% | −27—−103% | −8.0—−30.1% | — | — | |
| Net income attributable to shareholders | −5.1—−28.7% | −15—−62.2% | −141—−437% | −60—−148% | −33—−105% | −20—−70.1% | −27r−27—−103% | −8.0r−8.0—−30.1% | −13—−78.5% | −12—−94.3% | |
| Earnings per share, basic | -52.87—— | -45,711.05r-173.97—— | -15,925.99r-7.28—— | -4.65r-0.31—— | -0.21—— | -0.14—— | -0.21—— | -0.06—— | -0.13—— | -0.15—— | |
| Earnings per share, diluted | -52.87—— | -45,711.05r-175.99—— | -15,925.99r-7.28—— | -4.65r-0.31—— | -0.21—— | -0.14—— | -0.21—— | -0.06—— | -0.13—— | -0.15—— | |
| Shares, weighted average (basic) | 0.2+32946%— | 0.0r0.1−94.1%— | 0.0r21−99.9%— | 13r193−91.8%— | 156+12.5%— | 139+10.3%— | 126+1.3%— | 124+22.9%— | 101+26.7%— | 80—— | |
| Shares, weighted average (diluted) | 0.2+32946%— | 0.0r1.4−94.1%— | 0.0r21−99.9%— | 13r193−91.8%— | 156+12.5%— | 139+10.3%— | 126r126+1.3%— | 124r124+22.9%— | 101+26.7%— | 80—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.1+61.7%26.5% | 4.4+115%20.4% | 2.1−31.9%7.5% | 3.0r3.0+126%2.6% | 1.3+29.8%1.8% | 1.0+112%2.0% | 0.5r0.5−19.8%0.7% | 0.6−83.5%0.8% | 3.7−72.8%4.6% | 13—48.7% | |
| Short-term investments | — | — | — | 18−61.6%15.9% | 47+122%62.4% | 21−44.6%41.2% | 38r38−31.0%55.8% | 56−5.5%72.1% | 59—74.0% | 0—0.0% | |
| Receivables | 3.6+112%13.3% | 1.7+1.6%7.8% | 1.7+22.6%6.1% | 1.4r5.6+133%1.2% | 0.6−72.9%0.8% | 2.2+149%4.2% | 0.9r0.9−0.5%1.3% | 0.9−9.0%1.1% | 1.0+2235%1.2% | 0.0—0.1% | |
| Inventory | 4.3+115%16.0% | 2.0−53.6%9.3% | 4.3−40.2%15.8% | 7.3r10+152%6.3% | 2.9+41.6%3.8% | 2.0−10.2%3.9% | 2.3r2.3−25.6%3.3% | 3.0−7.3%3.9% | 3.3+6.1%4.1% | 3.1—11.2% | |
| Other current assets | 2.6+140%9.5% | 1.1−9.5%4.9% | 1.2−38.8%4.3% | 1.9r2.7−11.7%1.7% | 2.2+20.9%2.9% | 1.8+179%3.5% | 0.6r0.6−30.2%0.9% | 0.9+24.3%1.2% | 0.7+282%0.9% | 0.2—0.7% | |
| Current assets | 18+53.0%65.2% | 12−29.2%53.2% | 16−63.5%59.2% | 45−18.0%38.9% | 54+91.9%71.6% | 28−33.7%54.8% | 43r43−30.2%62.0% | 61−9.5%79.2% | 68+303%84.8% | 17—60.8% | |
| Property, plant and equipment | 2.4−12.0%9.0% | 2.8−18.3%12.8% | 3.4−8.1%12.3% | 3.7r13−36.8%3.2% | 5.8+135%7.7% | 2.5r2.7−33.3%4.8% | 3.7r3.7+14.1%5.4% | 3.3−1.7%4.2% | 3.3+36.2%4.2% | 2.4—8.8% | |
| Right-of-use (leased) assets | 0.7−55.6%2.7% | 1.6−13.5%7.6% | 1.9+101%6.9% | 0.9r2.7−45.3%0.8% | 1.7+598%2.3% | 0.2−59.0%0.5% | 0.6r0.6—0.9% | 0—0.0% | — | — | |
| Goodwill | — | — | 0−100%0.0% | 33—28.9% | 0—0.0% | — | — | — | — | — | |
| Other intangible assets | 6.2+8.7%23.0% | 5.7−3.4%26.4% | 5.9−17.9%21.5% | 7.2r17−8.9%6.3% | 7.9−3.6%10.4% | 8.2−3.3%15.9% | 8.5r8.5−12.9%12.3% | 9.8+31.1%12.6% | 7.4+0.6%9.3% | 7.4—26.7% | |
| Investments in associates | — | — | — | — | — | — | — | — | — | 1.0—3.7% | |
| Long-term investments | — | — | — | 0.7−70.9%0.6% | 2.3−64.1%3.1% | 6.5−22.2%12.6% | 8.4r8.4+172%12.2% | 3.1+126%4.0% | 1.4+33.9%1.7% | 1.0—3.7% | |
| Total assets | 27+24.7%100% | 22−21.2%100% | 28−76.0%100% | 115+50.9%100% | 76+46.9%100% | 52−25.0%100% | 69r69−10.8%100% | 77−3.1%100% | 80+188%100% | 28—100% | |
| Accounts payable | 1.0−58.4%3.7% | 2.4−46.0%11.1% | 4.4+117%16.2% | 2.1r4.2−5.6%1.8% | 2.2+94.7%2.9% | 1.1−44.1%2.2% | 2.0r2.0−22.4%2.9% | 2.6+23.7%3.3% | 2.1+55.3%2.6% | 1.3—4.8% | |
| Debt due within a year | — | 1.5−74.4%6.9% | 5.8—21.3% | — | — | — | — | — | — | — | |
| Current liabilities | 7.3−27.0%26.9% | 10.0−60.2%46.0% | 25+92.3%91.0% | 13+54.5%11.4% | 8.4+14.8%11.1% | 7.3+27.0%14.2% | 5.8r5.8+11.7%8.4% | 5.2+19.9%6.7% | 4.3+32.7%5.4% | 3.2—11.8% | |
| Long-term debt | — | 5.2−35.9%23.8% | 8.1—29.3% | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 0.6−58.2%2.2% | 1.4−15.4%6.6% | 1.7+139%6.2% | 0.7r2.1−50.3%0.6% | 1.4—1.9% | 0−100%0.0% | 0.4r0.4—0.6% | 0—0.0% | — | — | |
| Non-current liabilities | — | — | — | — | — | — | 1.1—1.6% | — | — | — | |
| Total liabilities | 8.5−51.7%31.6% | 18−50.8%81.5% | 36r36+92.3%131% | 19+89.0%16.3% | 9.9+30.3%13.0% | 7.6+9.9%14.7% | 6.9r6.9+14.6%10.0% | 6.0+39.6%7.8% | 4.3+30.4%5.4% | 3.3—12.0% | |
| Retained earnings | −399—−1476% | −394—−1817% | −379—−1377% | −238—−207% | −178—−234% | −145—−281% | −126r−126—−182% | −99—−128% | −91—−114% | −78—−283% | |
| Shareholders' equity | 16+293%58.3% | 4.0—18.5% | −8.4−109%−30.6% | 96+45.3%83.7% | 66+49.8%87.0% | 44−28.9%85.3% | 62r62−12.9%90.0% | 71r71−5.5%92.2% | 75r75+210%94.6% | 24—88.0% | |
| Total liabilities and equity | 27+24.7%100% | 22−21.2%100% | 28−76.0%100% | 115+50.9%100% | 76+46.9%100% | 52−25.0%100% | 69r69−10.8%100% | 77−3.1%100% | 80+188%100% | 28—100% | |
| Shares outstanding | 0.0r0.5+1025%— | 0.0r0.7−88.8%— | 0.0r44−99.9%— | 14r215−91.2%— | 163+17.1%— | 139+0.5%— | 138+11.0%— | 125+0.9%— | 124+36.2%— | 91—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | 2.9+129%7.1% | 1.2—4.0% | — | 1.2−1.1%4.6% | 1.2+41.3%4.5% | 0.8+14.1%5.1% | 0.7—6.1% | |
| Share-based compensation | 0.4+10.8%2.4% | 0.4−85.8%1.6% | 2.7−51.2%8.3% | 5.5+37.8%13.6% | 4.0+141%12.9% | 1.7−53.3%5.9% | 3.5r3.5+11.1%13.7% | 3.2r3.2+238%12.1% | 0.9+6.9%5.7% | 0.9—7.2% | |
| Cash from operating activities | −7.7—−43.9% | −14—−58.8% | −55—−171% | −52—−128% | −23—−73.8% | −16—−55.6% | −15r−15—−56.5% | −18r−18—−67.5% | −12—−72.7% | −9.9—−80.5% | |
| Capital expenditure | −0.1—−0.3% | −0.1—−0.6% | −4.7—−14.5% | −3.7—−9.0% | −0.7—−2.4% | −0.1—−0.2% | −0.5—−2.0% | — | — | — | |
| Intangible assets bought | −0.8—−4.6% | −0.0—−0.1% | −1.0—−3.0% | −0.8—−1.9% | −0.3—−1.1% | −0.5—−1.7% | −0.6r−0.5—−2.2% | −0.7r−0.7—−2.5% | −0.5—−2.7% | −0.4—−2.9% | |
| Acquisitions, net of cash acquired | — | — | −0.3—−0.8% | −1.3—−3.2% | — | — | — | — | — | — | |
| Cash from investing activities | −0.5—−2.9% | −0.1−101%−0.6% | 17−25.5%52.2% | 23—55.7% | −28−268%−89.6% | 16+262%58.6% | 4.6r4.6−69.9%17.6% | 15r15—57.3% | −61—−365% | −0.6—−4.5% | |
| Debt issued | — | — | 17—52.3% | — | — | 1.2—4.2% | — | — | — | — | |
| Debt repaid | −4.3—−24.5% | −1.3—−5.3% | −9.7—−30.1% | — | — | −1.2—−4.2% | — | — | — | — | |
| Shares issued | — | 16—66.2% | — | 35−12.5%86.4% | 40r38—129% | — | — | — | — | — | |
| Cash from financing activities | 11−35.0%62.3% | 17−54.7%69.1% | 37+20.7%116% | 31−39.4%76.1% | 51—164% | −0.3−103%−1.1% | 9.9r9.9—38.4% | −0.4r−0.4−101%−1.3% | 63+212%379% | 20—164% | |
| Change in cash | 2.7+15.4%15.5% | 2.4—9.7% | −1.0−157%−3.0% | 1.7+449%4.2% | 0.3−43.6%1.0% | 0.5—1.9% | −0.1r−0.1—−0.5% | −3.1r−3.1—−11.6% | −9.8−201%−59.1% | 9.7—79.1% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 15−27.4%100% | 2.9−29.9%100% | 4.1−31.1%100% | 3.5*−12.0%100% | 4.0−32.5%100% | 4.1−48.6%100% | 6.0−7.9%100% | 4.0*−45.3%100% | 5.9−24.5%100% | 7.9—100% | 6.5—100% | 7.4—100% | 7.9r18—100% | |
| Cost of revenue | 8.0−33.1%55.0% | 1.6−43.4%56.6% | 1.9−33.3%46.9% | 1.9*−39.2%53.2% | 2.6−17.6%63.7% | 2.9−26.0%70.1% | 2.9—48.4% | 3.1*—76.9% | 3.1—52.2% | 3.9—48.7% | — | — | — | |
| Research and development | 0.9+3.7%6.0% | 0.3+30.0%10.3% | 0.3+75.9%6.9% | 0.1*−51.8%3.0% | 0.2−19.6%4.8% | 0.2−9.2%5.6% | 0.2−61.9%2.7% | 0.2*−55.7%5.4% | 0.2−61.5%4.0% | 0.3—3.1% | 0.4—6.6% | 0.5*—6.7% | 0.6r1.6—7.9% | |
| Selling, general and administrative | 8.5−5.0%58.5% | 2.7+27.6%94.4% | 2.1+17.7%51.6% | 1.8*−26.2%51.6% | 1.8−27.4%46.1% | 2.1−10.2%51.9% | 1.8−38.1%30.2% | 2.5*−38.3%61.5% | 2.5−63.3%42.8% | 2.4—29.7% | 2.9—44.9% | 4.0*—54.5% | 6.9r11—88.2% | |
| Operating expenses | 9.5−4.1%65.6% | 3.0+27.8%105% | 2.4+22.5%58.5% | 2.0*−30.6%55.7% | 2.2−22.8%53.7% | 2.3−10.4%57.5% | 2.0−40.7%32.9% | 2.8*−55.7%70.6% | 2.8−66.5%46.9% | 2.6—32.9% | 3.3—51.1% | 6.4*—87.0% | 8.3r70—106% | |
| Operating income | −12—−85.0% | −3.3—−115% | −3.0—−74.0% | −2.8*—−79.2% | −3.2—−80.1% | −3.0—−73.0% | −2.6—−43.1% | −4.1*—−102% | −3.4—−56.8% | −2.0—−25.8% | −4.4—−68.5% | −14r64*—−193% | −8.3r−71—−105% | |
| Interest expense and finance costs | 0.6−61.4%4.0% | 0.0−95.2%0.6% | 0.0−98.0%0.3% | 0.0*−95.5%0.3% | 0.5+71.7%13.3% | 0.4−29.9%8.6% | 0.6−45.1%9.4% | 0.3*−95.9%6.6% | 0.3−76.2%5.2% | 0.5—6.3% | 1.0—15.7% | 6.4*—87.6% | 1.3—16.6% | |
| Other non-operating income (expense) | −0.5—−3.3% | 0.0—0.9% | 0.0—0.5% | 0.0*—0.7% | −0.6—−13.7% | −0.3—−8.5% | −0.7—−11.8% | −0.2*—−3.8% | −0.2−221%−3.5% | −0.1—−1.8% | −1.0—−15.7% | −7.8r−7.0*—−106% | 0.2r−1.2—2.2% | |
| Income before tax | −13—−88.3% | −3.3—−114% | −3.0—−73.5% | −2.8*—−78.5% | −3.8—−93.8% | −3.3—−81.6% | −3.3—−55.0% | −4.2*—−106% | −3.6—−60.3% | −2.2—−27.5% | −5.5—−84.2% | −22r57*—−300% | −8.1r−73—−103% | |
| Income tax | — | — | — | 0.0*+100%0.2% | 0*−100%0.0% | −0.0−231%−0.8% | — | 0.0*+200%0.1% | 0.0*—0.0% | 0.0—0.3% | — | 0.0*—0.0% | 0*—0.0% | |
| Income from continuing operations | −13—−88.4% | −3.3—−114% | −3.0—−73.5% | −2.8*—−78.7% | −3.8—−93.8% | −3.3—−80.7% | −3.3—−55.0% | −4.2*—−106% | −3.6—−60.3% | −2.2—−27.9% | −5.5—−84.2% | −22—−300% | −8.1—−103% | |
| Income from discontinued operations | 8.9—61.3% | −0.1—−2.8% | −0.2—−5.9% | −0.0*—−0.7% | 9.3—231% | −0.1−110%−2.7% | −1.1—−17.7% | −0.3*—−7.7% | −0.2—−2.9% | 1.1—13.9% | −0.3—−4.5% | −7.3*—−98.8% | −65—−821% | |
| Net income including minority interests | −3.9—−27.0% | −3.3*—−117% | −3.3—−79.4% | −2.8*—−79.4% | 5.5*—137% | −3.4*—−83.4% | −4.3—−72.7% | −4.6*—−113% | −3.8*—−63.2% | −1.1*—−14.0% | −5.7—−88.7% | −29*—−399% | −73*—−924% | |
| Net income attributable to shareholders | −3.9—−27.0% | −3.3—−117% | −3.3—−79.4% | −2.8*—−79.4% | 5.5—137% | −3.4—−83.4% | −4.3—−72.7% | −4.6*—−113% | −3.8—−63.2% | −1.1—−14.0% | −5.7—−88.7% | −29*—−399% | −73—−924% | |
| Earnings per share, basic | — | -104.00—— | -18.08—— | — | 1.55—— | -3,390.05r-13.61—— | -838.43r-2.50—— | — | -1,760.26r-0.55—— | -593.72r-0.21—— | -395.07r-2.94—— | — | -60.75r-3.68—— | |
| Earnings per share, diluted | — | -104.00—— | -18.08—— | — | -0.28—— | -3,390.05r-13.61—— | -838.43r-2.50—— | — | -1,760.26r-0.55—— | -593.72r-0.21—— | -395.07r-2.94—— | — | -60.75r-3.48—— | |
| Shares, weighted average (basic) | 0.2+20720%— | 0.2+20720%— | 0.6+11433%— | — | 3.5+83758%— | 0.0r0.3−61.7%— | 0.0r1.7−78.1%— | — | 0.0r14−99.6%— | 0.0r7.4—— | 0.0r3.2—— | — | 1.2r20—— | |
| Shares, weighted average (diluted) | 0.2+20720%— | 0.2+20720%— | 0.6+11433%— | — | 12+165432%— | 0.0r0.3−61.7%— | 0.0r1.7−78.1%— | — | 0.0r14−99.4%— | 0.0r7.4—— | 0.0r3.2—— | — | 1.2r20—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.1—23.2% | 6.1+96.5%23.2% | 9.5+742%31.5% | 7.1+61.7%26.5% | 4.8−9.3%15.0% | 3.1+141%13.8% | 1.1−25.3%5.3% | 4.4+115%20.4% | 5.3+87.4%20.4% | 1.3—5.3% | 1.5—6.2% | 2.1—7.5% | 2.9—4.4% | |
| Receivables | 3.6—13.7% | 3.6+1.0%13.7% | 4.8+10.6%15.8% | 3.6+112%13.3% | 3.0+67.8%9.2% | 3.5+44.6%15.8% | 4.3+147%20.1% | 1.7+1.6%7.8% | 1.8−72.5%6.8% | 2.4—10.2% | 1.7—7.1% | 1.7—6.1% | 6.5—10.1% | |
| Inventory | 4.5—17.3% | 4.5+81.2%17.3% | 4.3+70.1%14.3% | 4.3+115%16.0% | 2.9+24.2%9.0% | 2.5−6.0%11.2% | 2.6−11.6%11.9% | 2.0−53.6%9.3% | 2.3−85.3%8.9% | 2.7—11.1% | 2.9—11.7% | 4.3—15.8% | 16—24.9% | |
| Other current assets | 2.7—10.1% | 2.7−3.4%10.1% | 2.4+53.9%7.9% | 2.6+140%9.5% | 2.7+174%8.3% | 2.7+55.2%12.3% | 1.6+123%7.3% | 1.1−9.5%4.9% | 1.0−79.7%3.7% | 1.8—7.3% | 0.7—2.8% | 1.2—4.3% | 4.8—7.5% | |
| Current assets | 17—64.3% | 17+41.7%64.3% | 21+89.9%69.5% | 18+53.0%65.2% | 23+45.4%70.8% | 12−12.0%53.0% | 11−19.1%51.7% | 12−29.2%53.2% | 16−61.2%60.2% | 13—56.0% | 14—55.7% | 16—59.2% | 41—63.3% | |
| Property, plant and equipment | 2.6—9.9% | 2.6+1.1%9.9% | 2.4−11.1%7.8% | 2.4−12.0%9.0% | 2.5−17.4%7.6% | 2.6−17.0%11.5% | 2.7−17.7%12.4% | 2.8−18.3%12.8% | 3.0−68.1%11.3% | 3.1—12.8% | 3.2—13.1% | 3.4—12.3% | 9.3—14.5% | |
| Right-of-use (leased) assets | 0.6—2.5% | 0.6−57.0%2.5% | 0.7−56.2%2.3% | 0.7−55.6%2.7% | 0.8−55.0%2.4% | 1.5−15.0%6.7% | 1.6−14.2%7.3% | 1.6−13.5%7.6% | 1.7−42.9%6.5% | 1.8—7.3% | 1.8—7.4% | 1.9—6.9% | 3.0—4.6% | |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | |
| Other intangible assets | 6.1—23.2% | 6.1−5.8%23.2% | 6.1+0.4%20.2% | 6.2+8.7%23.0% | 6.2+8.5%19.2% | 6.4+12.2%28.7% | 6.1+5.1%28.5% | 5.7−3.4%26.4% | 5.7−17.0%21.9% | 5.7—23.8% | 5.8—23.6% | 5.9—21.5% | 6.9—10.7% | |
| Long-term investments | — | — | — | — | — | — | — | — | — | — | — | — | 0.7—1.1% | |
| Total assets | 26—100% | 26+16.9%100% | 30+41.3%100% | 27+24.7%100% | 32+23.6%100% | 22−7.1%100% | 21−12.8%100% | 22−21.2%100% | 26−59.2%100% | 24—100% | 25—100% | 28—100% | 64—100% | |
| Accounts payable | 0.7—2.7% | 0.7−75.9%2.7% | 1.0−66.8%3.4% | 1.0−58.4%3.7% | 2.6−16.1%8.0% | 2.9−25.8%12.9% | 3.1−38.8%14.4% | 2.4−46.0%11.1% | 3.1−55.8%11.8% | 3.9—16.2% | 5.0—20.5% | 4.4—16.2% | 7.0—10.9% | |
| Debt due within a year | — | — | — | — | — | 3.2+114%14.4% | 3.9−40.3%18.3% | 1.5−74.4%6.9% | 1.5−91.7%5.7% | 1.5—6.2% | 6.6—26.7% | 5.8—21.3% | 18—28.3% | |
| Current liabilities | 6.5—24.7% | 6.5−58.1%24.7% | 7.9−51.8%26.1% | 7.3−27.0%26.9% | 11−27.0%32.6% | 15−4.2%68.8% | 16−35.1%76.4% | 10.0−60.2%46.0% | 14−63.7%55.2% | 16—66.7% | 25—103% | 25—91.0% | 40—61.9% | |
| Long-term debt | — | — | — | — | — | — | — | 5.2−35.9%23.8% | 5.5—21.1% | 6.0—25.1% | 8.1—33.1% | 8.1—29.3% | — | |
| Lease liabilities (non-current) | 0.5—2.0% | 0.5−60.3%2.0% | 0.6−59.2%1.8% | 0.6−58.2%2.2% | 0.6−57.2%2.0% | 1.3−18.0%5.8% | 1.4−16.6%6.4% | 1.4−15.4%6.6% | 1.5−75.8%5.8% | 1.6—6.5% | 1.6—6.6% | 1.7—6.2% | 6.2—9.7% | |
| Total liabilities | 7.5—28.8% | 7.5−55.1%28.8% | 9.1−49.0%30.0% | 8.5−51.7%31.6% | 11−50.4%34.8% | 17−33.1%74.8% | 18−50.8%83.1% | 18−50.8%81.5% | 23−54.9%86.7% | 25—104% | 36—147% | 36r36—131% | 50—78.5% | |
| Retained earnings | −406—−1550% | −406—−1550% | −402—−1327% | −399—−1476% | −396—−1224% | −402—−1794% | −398—−1856% | −394—−1817% | −389—−1487% | −386—−1601% | −384—−1562% | −379—−1377% | −379r−349—−590% | |
| Shareholders' equity | 19—71.2% | 19+231%71.2% | 21+485%70.0% | 16+293%58.3% | 18+429%56.8% | 5.6—25.2% | 3.6—16.9% | 4.0—18.5% | 3.5−74.8%13.3% | −1.0—−4.0% | −12—−47.2% | −8.4—−30.6% | 14—21.5% | |
| Total liabilities and equity | 26—100% | 26+16.9%100% | 30+41.3%100% | 27+24.7%100% | 32+23.6%100% | 22−7.1%100% | 21−12.8%100% | 22−21.2%100% | 26−59.2%100% | 24—100% | 25—100% | 28—100% | 64—100% | |
| Shares outstanding | 0.5—— | 0.5+9.6%— | 0.8−71.8%— | 0.0r0.5+1025%— | — | 0.5−95.1%— | 2.7−24.1%— | 0.0r0.7−88.8%— | 29+39.4%— | 9.3—— | 3.6—— | 0.0r44—— | 21—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.8—5.5% | 0.3*+152%9.4% | 0.2+815%5.8% | 0.2*+33.3%5.5% | 0.1*—2.3% | 0.1*+91.1%2.6% | 0.0−85.6%0.4% | 0.1*—3.7% | — | 0.1*—0.7% | 0.2—2.8% | — | 0.6—7.3% | |
| Cash from operating activities | −8.4—−57.6% | −4.0*—−139% | −3.1—−75.6% | 2.7*—77.7% | −4.0*—−100% | −3.5*—−85.2% | −3.0—−50.0% | −4.4*—−109% | −3.0*—−50.1% | −4.7*—−59.3% | −2.3—−34.9% | −4.8*—−65.3% | −13*—−163% | |
| Capital expenditure | −0.4—−2.7% | −0.3*—−11.6% | −0.0—−1.0% | −0.0*—−0.5% | −0.0*—−0.1% | −0.0*—−0.7% | −0.0—−0.2% | 0*—0.0% | −0.1*—−1.2% | −0.1*—−0.8% | −0.0—−0.1% | −0.7*—−9.6% | −1.2*—−15.1% | |
| Intangible assets bought | −0.8—−5.3% | −0.0*—−0.1% | −0.0—−0.2% | −0.7*—−20.9% | −0.0*—−0.4% | −0.0*—−0.2% | −0.0—−0.8% | — | — | — | — | −0.5*—−7.2% | −0.0*—−0.4% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | −0.3*—−4.4% | |
| Cash from investing activities | −1.5−364%−10.6% | −0.3*−142%−10.8% | −0.0—−1.1% | −0.7*—−18.5% | −0.5*—−13.0% | 0.7*—17.9% | −0.1−493%−1.0% | −0.0*—−0.5% | −0.1*—−1.2% | −0.1*—−0.8% | 0.0—0.2% | −0.5*—−7.3% | −1.6*—−20.0% | |
| Debt issued | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | |
| Debt repaid | — | — | — | 0*—0.0% | −1.0—−25.4% | −1.0—−24.9% | — | −0.6*—−15.7% | −0.4*—−7.1% | — | — | — | — | |
| Shares issued | — | 0*—0.0% | 0.2—4.9% | — | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 13−14.5%88.7% | 0.8*−82.7%28.4% | 5.5—135% | 0.2*−94.0%5.9% | 6.3*−11.3%157% | 4.7*+3.4%115% | −0.3−115%−4.3% | 3.5*—87.0% | 7.1*−44.6%120% | 4.5*—57.1% | 1.7—26.3% | −3.0*—−40.1% | 13*—163% | |
| Change in cash | 3.0+64.9%20.5% | −3.5*−279%−122% | 2.4—58.4% | 2.3*—65.1% | 1.8*−56.6%44.0% | 2.0*—47.8% | −3.3—−55.2% | −0.9*—−22.9% | 4.1*—68.3% | −0.2*—−3.0% | −0.5—−8.4% | −8.3*—−113% | −1.6*—−20.1% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What 22Nd Century Group, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Contract Manufacturing$17 M99%-28%
- Cigarettes$13 M73%-9.3%
- Filtered Cigars$4 M23%-56%
- Other tobacco products$0 M2.5%-42%
- VLN$0 M0.8%—
Business segments
- Single reportable segment$18 M100%-28%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where 22Nd Century Group, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 12 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at 22Nd Century Group, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 3 · Material agreement 10 · Agreement ended 2 · Unregistered share sale 2 · Shareholder rights changed 8 · Bylaws or fiscal year changed 9 · Shareholder vote 4 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Agreement ended | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K/A | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder voteResults announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officersMaterial agreementResults announced | 8-K | |
| Agreement ended | 8-K | |
| Auditor changed | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 3, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2024 | $1 M | Private placement after listing | Under $2 million | 7 | equity, options | SEC |
| Apr 2024 | $4 M | Private placement after listing | $2 to $10 million | 9 | equity, options | SEC |
| Jul 2022 | $35 M | Private placement after listing | $10 to $50 million | 14 | equity, options | SEC |
| May 2022 | $58 M | Private placement after listing | $50 to $250 million | 64 | equity | SEC |
| Sep 2014 | $10 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Nov 2012 | $2 M | No. 3 | $2 to $10 million | 20 | equity, options | SEC |
| May 2012 | $3 M | No. 2 | $2 to $10 million | 19 | equity, options | SEC |
| Dec 2011 | $2 M | No. 1 | Under $2 million | 24 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by 22Nd Century Group, Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2022.
Lobbying firms hired in 2022
Foley & Lardner, LLP
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $0 | — | 1 |
| 2021 | $260 K | — | 4 |
| 2020 | $70 K | — | 1 |
| 2019 | $40 K | — | 3 |
| 2018 | $120 K | — | 5 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “22nd Century Group, Inc.” and “22nd Century”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How 22Nd Century Group, Inc. compares in Pharmaceutical
- Market cap$0 M · higher than 0% of 393
- Revenue$18 M · higher than 8% of 324
- Net margin-27.0% · higher than 12% of 313
- Revenue growth-27.9% · higher than 8% of 107
- Price / sales0.0× · lowest of 219
- Price / book0.0× · lowest of 207
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| 22Nd Century Group, Inc.🇺🇸 | $0 M | — | -27.0% | -27.9% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Venus Remedies Limited$215 M
- Windlas Biotech Limited$217 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at 22Nd Century Group, Inc.? Verify and update this profile — free
Show 22Nd Century Group, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.